ステアトス性肝疾患と慢性腎疾患の関連性:メタ解析とメンデルのランダム化研究で,代謝併発症を強調した
Xiang Ji1,2, Jinguo Jiang1,2, Yunyun Liu3
1Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.
Nutrition & diabetes
|February 23, 2026
まとめ
MAFLD,NAFLD,MASLDを含むステアトス性肝疾患 (SLD) は,慢性腎臓疾患 (CKD) のリスクの増加と関連しています. しかし,SLDそのものではなく,代謝的要因がCKD発症を誘発しているようです.
科学分野:
- ヘパトロジーと腎臓病理学
- メタボリック疾患
- エピデミオロジー エピデミオロジー
背景:
- 代謝関連脂肪肝疾患 (MAFLD),非アルコール性脂肪肝疾患 (NAFLD),代謝機能障害関連脂肪肝疾患 (MASLD),慢性腎臓疾患 (CKD) を含むステアトス性肝疾患 (SLD) は,世界的な健康上の大きな課題である.
- メタボリック要因は,MAFLDとMASLDの定義の中心であり,CKDとの関連に影響を与える可能性があります.
研究 の 目的:
- SLDとCKDリスクとの関連に関するメタ解析を更新する.
- 2つのサンプルのメンデルのランダム化 (MR) 分析を行い,SLDとCKDにおける代謝因子の因果的役割を調査する.
主な方法:
- 2024年11月までのPubMed,Embase,Web of Scienceの体系的な文献検索を行いました.
- ランダム効果モデルを用いたメタ分析により,95%信頼区間 (CI) を有するオッズ比 (ORs) をまとめました.
- 逆変数加重法 (IVW) と感度分析を用いた2サンプルMR分析.
主要な成果:
- 34件の研究 (3,783,136人の参加者) のメタアナリシスは,CKDとMAFLD,NAFLD,MASLDとの間に有意なポジティブな関連性を示しました.
- MR分析では,SLDがCKDリスクに因果的な影響を与えないことが判明しました.
- 遺伝学的に予測された代謝因子 (BMI,腰周,2型糖尿病,血圧,脂質) は,CKDリスクの増加と有意に関連していました.
結論:
- SLDは,CKDのリスクの増加と有意に関連しています.
- SLD自体ではなく,代謝機能障害が,CKDリスクの主な要因であるようです.
- SLD患者の代謝健康に関する早期スクリーニングと介入は,CKDの負担を軽減するために重要である.
関連する概念動画
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
243
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
243
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
294
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
294
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
266
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
266
01:28Chronic Kidney Disease III: Interprofessional Care
503
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
503
01:24Chronic Kidney Disease II: Clinical Manifestations
760
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
760
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
247
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
247